Loading patent…
AssigneeAgensys, Inc.
InventorsJean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Pia M. Challita-Eid, Arthur B. Raitano
Estimating the term…
Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
A monoclonal antibody comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, wherein the monoclonal antibody comprises the amino acid sequence of the variable heavy chain region and the variable light chain region of the antibody secreted by the hybridoma assigned A.T.C.C. Accession No.:
A monoclonal antibody fragment comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.